Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. It does not contain financial results, operational updates, or strategic commentary for the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of specific share transactions and does not report consolidated financial performance.
Material Changes and Transaction Details
The filing discloses three separate transactions executed on February 18, 2021, on the New York Stock Exchange (XNYS). All transactions involved the acquisition of American Depositary Shares (ADSs) at a price of $34.70 per share. The acquisitions were driven by dividend reinvestment plans rather than open market purchases.
- Dr. H. Barron (Chief Scientific Officer and President, R&D): Acquired 2,830.834 notional ADSs via the GSK Executive Supplemental Savings Plan.
- Dr. H. Barron (Chief Scientific Officer and President, R&D): Acquired 71 ADSs via the GSK 401(k) plan.
- Mr. J. Ford (SVP & General Counsel): Acquired 86.490 notional ADSs via the GSK Executive Supplemental Savings Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory reporting of the aforementioned share transactions.
Key Facts for Investor Verification
- Verify the total number of ADSs held by Dr. Barron and Mr. Ford following these dividend reinvestment transactions.
- Confirm that the transaction price of $34.70 aligns with the market price of GSK ADSs on February 18, 2021.
- Note that these transactions are passive acquisitions resulting from dividend reinvestment, not active trading decisions by the executives.
- Check subsequent filings for any sales or further acquisitions by these PDMRs to assess net position changes.